COMPARATIVE CHEMOSENSITIVITY PROFILES IN 4 HUMAN OVARIAN-CARCINOMA CELL-LINES MEASURING ATP BIOLUMINESCENCE

被引:55
作者
PETRU, E [1 ]
SEVIN, BU [1 ]
PERRAS, J [1 ]
BOIKE, G [1 ]
RAMOS, R [1 ]
NGUYEN, H [1 ]
AVERETTE, HE [1 ]
机构
[1] UNIV MIAMI,SCH MED,DEPT OBSTET & GYNECOL,DIV GYNECOL ONCOL,MIAMI,FL 33101
关键词
D O I
10.1016/0090-8258(90)90032-G
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
cis-Platinum (DDP) and cyclophosphamide are commonly used for the treatment of ovarian cancer; however, survival remains poor. The degree of cytotoxicity of the standard antineoplastic agents DDP, 4-hydroperoxy-cyclophosphamide (4-OH-CTX), mitomycin C (MITOM C), vincristine (VCR), etoposide (VP-16), 5-fluorouracil (5-FU), cytosine arabinoside (ARA-C), and interferon (IF) in four representative ovarian cancer cell lines was studied using the ATP assay, which measures total cell kill. Cell lines CAOV-3, OVCAR-3, SKOV-3, and BG-1, which were derived from both pretreated and untreated patients, were exposed to six different concentrations for 90 min. On Day 7, intracellular ATP determinations were done. Sensitivity was defined as ≥50% cell kill at 0.5× peak plasma concentration as compared to controls. For 4-OH-CTX and ARA-C, 3 and 0.5 μg/ml were chosen as 0.5× reference values. For each drug in each cell line, a highly reproducible dose-response relationship was observed. CAOV-3 cells were sensitive to all drugs except DDP, ARA-C, and IF, and OVCAR-3 cells to all except DDP and IF. SKOV-3 cells were resistant to all agents except VCR, and BG-1 cells to all except MITOM C and 5-FU. The apparent heterogeneic response to antineoplastic agents observed in the above cell lines underscores the importance of assessing individual patients' sensitivity profiles before treatment. © 1990.
引用
收藏
页码:155 / 160
页数:6
相关论文
共 23 条
[1]  
Alberts DS, 1980, CLONING HUMAN TUMOR, P351
[2]  
BUICK RN, 1985, CANCER RES, V45, P3668
[3]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[4]   CHEMICAL MODIFIERS OF CANCER-TREATMENT [J].
COLEMAN, CN ;
BUMP, EA ;
KRAMER, RA .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (04) :709-733
[5]   REVIEW - BIOLOGIC HETEROGENEITY OF CANCER METASTASES [J].
FIDLER, IJ .
BREAST CANCER RESEARCH AND TREATMENT, 1987, 9 (01) :17-26
[6]  
Fogh J., 1975, HUMAN TUMOR CELLS IN, P115
[7]  
FOJO A, 1987, CANCER-AM CANCER SOC, V60, P2075, DOI 10.1002/1097-0142(19901015)60:8+<2075::AID-CNCR2820601521>3.0.CO
[8]  
2-F
[9]  
GAREWAL HS, 1986, J NATL CANCER I, V77, P1039
[10]  
GIESINGER K, 1989, CANCER, V63, P280